A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cited by
Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer
Tsay, J.-C. J., Wu, B. G., Badri, M. H., Clemente, J. C., Shen, N., Meyn, P., Li, Y., Yie, T.-A., Lhakhang, T., Olsen, E., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2118oc · Cited by 448
Le-Rademacher, J., Hillman, S. L., Meyers, J., Loprinzi, C. L., Limburg, P. J., & Mandrekar, S. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx043 · Cited by 24
“Observed patterns: cancer prevention trials In cancer prevention setting (MAYO 04-4-01 [11], MAYO 1015-03 [12], MAYO 03-1-02 [13], MAYO 06-8-01 [14] and MAYO 03-10-3 [15]), the number of AEs reported was low and <7% were Grade 3–5 events (results are shown in Table 4).”
BackgroundSelf-citationThe "asthma-polycystic ovary overlap syndrome" and the therapeutic role of myo-inositol
Guarnieri, G., Iervolino, M., Cavallone, S., Unfer, V., & Vianello, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086959 · Cited by 11
Metadata
- Authors
- Lam, S., Mandrekar, S. J., Gesthalter, Y., Allen Ziegler, K. L., Seisler, D. K., Midthun, D. E., Mao, J. T., Aubry, M. C., McWilliams, A., Sin, D. D., Shaipanich, T., Liu, G., Johnson, E., Bild, A., Lenburg, M. E., Ionescu, D. N., Mayo, J., Yi, J. (., Tazelaar, H., Harmsen, W. S., Smith, J., Spira, A. E., Beane, J., Limburg, P. J., & Szabo, E.
- Venue
- Cancer Prevention Research
- Published
- 2016-12-01
- Volume
- 9
- Issue
- 12
- Pages
- 906-914
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- OpenAlex
- W2522736967
- Cited by
- 35
- References
- 1
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia. https://app.cochat.ai/papers/10.1158/1940-6207.capr-15-0254
- The paper
- Lam, S., Mandrekar, S. J., Gesthalter, Y., Allen Ziegler, K. L., Seisler, D. K., Midthun, D. E., Mao, J. T., Aubry, M. C., McWilliams, A., Sin, D. D., Shaipanich, T., Liu, G., Johnson, E., Bild, A., Lenburg, M. E., Ionescu, D. N., Mayo, J., Yi, J. (., Tazelaar, H., . . . Szabo, E. (2016). A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia. Cancer Prevention Research. https://doi.org/10.1158/1940-6207.capr-15-0254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.